CD19 and acute lymphoblastic leukemia: To address antigen-negative relapse, which occurs in approximately 20% of CD19-CAR-T cell-treated patients (in BCP-ALL) [2], multitargeted CAR T cell products have been developed and are used in various formats as tandem CAR constructs or bicistronic or even tri-valent CAR constructs [80,84,108].